Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) EBT Margin (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed EBT Margin for 9 consecutive years, with 5864.29% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBT Margin fell 111934.0% year-over-year to 5864.29%, compared with a TTM value of 7627.13% through Jun 2025, down 191852.0%, and an annual FY2025 reading of 4689.82%, up 325489.0% over the prior year.
  • EBT Margin was 5864.29% for Q2 2025 at VYNE Therapeutics, down from 4258.91% in the prior quarter.
  • Across five years, EBT Margin topped out at 3230.77% in Q4 2021 and bottomed at 26717.24% in Q4 2022.
  • Average EBT Margin over 5 years is 7839.03%, with a median of 6052.64% recorded in 2025.
  • The sharpest move saw EBT Margin plummeted -2348647bps in 2022, then soared 1862382bps in 2023.
  • Year by year, EBT Margin stood at 3230.77% in 2021, then plummeted by -727bps to 26717.24% in 2022, then soared by 70bps to 8093.42% in 2023, then crashed by -77bps to 14297.62% in 2024, then skyrocketed by 59bps to 5864.29% in 2025.
  • Business Quant data shows EBT Margin for VYNE at 5864.29% in Q2 2025, 4258.91% in Q1 2025, and 14297.62% in Q4 2024.